The 'cation-dependent' mannose 6-phosphate receptor binds ligands in the absence of divalent cations

Ulrich Junghans, Abdul Waheed and Kurt von Figura

Universität Göttingen, Zentrum Biochemie, Abt. Biochemie II, Gosslerstr. 12d, D 3400 Göttingen, FRG

Received 22 July 1988

The requirement of divalent cations for binding of the 46 kDa mannose 6-phosphate receptors to phosphomannan and pentamannose 6-phosphate-substituted bovine serum albumin was examined. Receptors from human liver and human brain bound to both affinity ligands in the absence or presence of divalent cations with similar efficiency. The requirement for divalent cations therefore appears not to be necessary for the binding.

Lysosomal enzyme; Enzyme receptor; Mannose 6-phosphate receptor

1. INTRODUCTION

Two mannose 6-phosphate receptors (MPR) are known which differ in molecular mass, binding specificity and function. The larger of the two (MPR 215) has an apparent molecular mass of 215 kDa (this receptor has recently been cloned and shown to be identical with the IGF II receptor; the cDNA predicts a size of about 275 kDa for the receptor polypeptide [15]) and binds mannose 6-phosphate-containing ligands in the absence of divalent cations [1]. Binding of the ligands to the smaller receptor (MPR-46) with an apparent molecular mass of 46 kDa was reported to have an absolute requirement for divalent cations [2]. This property has led to the designation of the smaller receptor as cation-dependent MPR (MPR^{CD}) and has been employed to separate MPR-46 and MPR-215 from lysates of Chinese hamster ovary cells [3].

We had previously noted that binding of a mannose 6-phosphate-neoglycoprotein to MPR-46bearing membranes of Morris hepatoma 7777 cells was largely independent of divalent cations [4].

Correspondence address: K. von Figura, Universität Göttingen, Biochemie II, Gosslerstr. 12d, D 3400 Göttingen, FRG.

The lack of cation requirement for binding was attributed to the unusually large amount of mannose 6-phosphate in the neoglycoprotein (≥ 30 mol per mol polypeptide) [5]. We were later unable to separate MPR-215 from MPR-46 on the basis of their differential requirement of cations for high-affinity binding. This prompted us to reinvestigate the effect of divalent cations on the binding of MPR-46 with annose 6-phosphate-containing ligands.

2. MATERIALS AND METHODS

2.1. Materials

MPR-46 purified from human liver [6] was [125] liodinated with the aid of iodogen (Pierce) according to Parker et al. [7] to a specific activity of 2500 cpm/ng receptor. Pentamannose 6-phosphate-substituted bovine serum albumin (PMP-BSA) was kindly provided by Dr T. Braulke of this institute [5]. Phosphomannan-Sepharose 4B, Dictyostelium discoideum lysosomal enzyme-Sepharose 4B and rabbit antisera against human liver MPR-215 and MPR-46 were those previously described [6,8].

2.2. Binding of ¹²⁵I-MPR-46 to phosphomannan-Sepharose 4B ¹²⁵I-MPR-46 (40 000 cpm in 100 μl binding buffer: 50 mM imidazole/150 mM NaCl/5 mM Na β-glycerophosphate/0.05% Triton X-100/0.05% BSA) containing either 10 mM MgCl₂ or 2 mM EDTA was loaded on phosphomannan-Sepharose 4B columns (500 μl bed volume) at 4°C and incubated for 5 min. Each

column was washed under its loading conditions with 8 ml binding buffer followed by 5 ml binding buffer/2 mM EDTA. The receptor was eluted with 6 ml of 0.5 mM mannose 6-phosphate in binding buffer. The fraction was assayed for radioactivity, pooled as indicated in fig.1, dialyzed against 10 mM NH₄ acetate, pH 7.0/0.05% Triton X-100 and lyophilized. Samples were dissolved in H₂O and precipitated with 80% acetone. One tenth of each sample was applied to SDS-PAGE [9]. The ¹²⁵I-MPR was visualized by autoradiography.

2.3. Solid-phase binding assay

Flexible microtiter wells were incubated for 6 h with 200 or 500 ng PMP-BSA in 50 μ l of 25 mM Tris-HCl, pH 7.0. The wells were washed 5 times with 50 mM Hepes/150 mM NaCl/0.1% Tween 20/0.1% Triton X-100/0.1% BSA and saturated overnight in the same buffer. ¹²⁵I-MPR-46 (20 000 cpm in 20 μ l of 50 mM Na phosphate, pH 7.0/150 mM NaCl/5 mM Na β -glycerophosphate/0.1% Triton X-100/0.1% BSA, supplemented with EDTA, MgCl₂ and mannose 6-phosphate as indicated in table 1) was added. After 3 h incubation the wells were washed 5 times with the phosphate buffer/6 mM MgCl₂, dried, cut and counted.

2.4. Purification of MPR-46 from human brain

MPR-46 from human brain was purified in the presence and absence of divalent cations: typically 10 g human brain (pooled material from cortex and white matter obtained after brain surgery) was homogenized in 20 ml of 50 mM imidazole, pH 7.0/150 mM NaCl/5 mM Na \(\beta\)-glycerophosphate/0.1 TIU/ml aprotinin/5 mM iodoacetamide/1 mM EDTA/1 mM phenylmethylsulfonyl fluoride (buffer A) and centrifuged at $1000 \times g$. The pellet was resuspended in buffer A and spun again at $1000 \times g$. The 1000 × g supernatants were pooled and centrifuged for 1 h at $100\,000 \times g$. The pellet was extracted overnight in 30 ml buffer A substituted with 1% Triton X-100/0.1% Na deoxycholate. After centrifugation for 1 h at $100000 \times g$, the supernatant was applied to the D. discoideum lysosomal enzyme-Sepharose 4B column [6] either directly or after adjusting to 10 mM MnCl₂. The flow-through (50 ml) was applied to the phosphomannan-Sepharose 4B column (15 ml bed volume). phosphomannan-Sepharose 4B was washed with 3 l of either buffer A/5 mM EDTA or buffer A/10 mM MnCl₂ prior to elution with 120 ml buffer A/2 mM mannose 6-phosphate. The eluents were analyzed by Western blotting [10] with a 1:1 mixture of antisera against MPR-215 and MPR-46.

3. RESULTS

3.1. Binding of ¹²⁵I-MPR-46 to phosphomannan-Sepharose 4B

MPR-46 purified to homogeneity from human liver was iodinated and assayed for binding to phosphomannan-Sepharose 4B in the presence of either 10 mM MgCl₂ or 2 mM EDTA. More than 70% of the receptor bound to the column under both conditions (fig.1). Receptor that was bound to the column in the presence of 10 mM MgCl₂




Fig. 1. Binding of ¹²⁵I-MPR-46 to phosphomannan-Sepharose 4B. ¹²⁵I-MPR-46 was loaded on the column in the presence of 10 mM MgCl₂ (O—O) or 2 mM EDTA (•••). After washing under loading conditions the columns were eluted sequentially with 2 mM EDTA and 0.5 mM mannose 6-phosphate (M6P) as indicated by arrows. Fractions of 1 ml were collected, assayed for radioactivity (bottom), pooled as indicated by horizontal bars and analyzed by SDS-PAGE followed by autoradiography (top). The position of MPR-46 is shown. A compression effect on MPR-46 by the high amounts of BSA in the sample can be noted.

could not be eluted with 2 mM EDTA and required 0.5 mM mannose 6-phosphate for release from the affinity matrix. This indicated that binding of ¹²⁵I-MPR-46 to phosphomannan-Sepharose 4B did not depend on divalent cations.

3.2. Binding of 125 I-MPR-46 to PMP-BSA

To examine the binding of ¹²⁵I-MPR-46 to immobilized PMP-BSA, microtiter wells coated with PMP-BSA were incubated with ¹²⁵I-MPR-46 in the presence of 6 mM MgCl₂ or 2 mM EDTA. Under both conditions, low but similar amounts of ¹²⁵I-MPR-46 bound to the solid phase (table 1). The binding was specific as indicated by the sensitivity to 5 mM mannose 6-phosphate.

3.3. Isolation of MPR-46 from human brain by affinity chromatography in the absence of divalent cations

The previous experiments had shown that binding of iodinated MPR-46 with mannose 6-phosphate-containing ligands did not require divalent cations. To exclude the possibility that the lack of cation requirement was a result of secondary modifications of the receptor during storage or iodination, we investigated whether purification of MPR-46 on a phosphomannan-Sepharose 4B column could be achieved in the absence of divalent cations.

A membrane extract from human brain was passed through a *D. discoideum* lysosomal enzyme-Sepharose 4B column to remove MPR-215 [2] and then over a phosphomannan-Sepharose 4B column (an affinity matrix for both types of MPR, see [2]). After extensive washing the columns were eluted with 2 mM mannose 6-phosphate. The eluents were analyzed for the presence of the two receptors by Western blotting with a mixture of antisera against MPR-46 and MPR-215. In eluents of

Table 1

Binding of ¹²⁵I-MPR-46 to microtiter wells coated with PMP-BSA

| Bound 125I-MPR (cpm) | |
|----------------------|--------------------|
| Α | В |
| 108 ± 1 | 132 ± 8 |
| 22 | |
| 92 ± 4 | 135 ± 23 |
| 2 | 21 |
| | A 108 ± 1 22 |

Wells were coated with 200 (A) or 500 (B) ng PMP-BSA. The values for EDTA and $MgCl_2$ give the mean and range of duplicates. All values were corrected for background binding to wells coated with BSA alone (19 \pm 4 and 49 \pm 7 cpm in series A and B, respectively)




Fig.2. Western blot of MPR-46 from human brain. Brain extracts were chromatographed sequentially on *D. discoideum* lysosomal enzyme-Sepharose 4B and phosphomannan-Sepharose 4B columns in the presence of MnCl₂ (lane 2) or EDTA (lane 3). Aliquots of the mannose 6-phosphate eluents from phosphomannan-Sepharose 4B corresponding to 0.2 g fresh tissue and 200 ng human liver MPR-46 (lane 1) were separated by SDS-PAGE, transferred to nitrocellulose and analyzed with a mixture of antisera against MPR-46 and MPR-215. The monomeric and dimeric forms of MPR-46 are marked (->). MPR-215 polypeptides (-) representing intact recepotor and an approx. 130 kDa fragment are present in lane 3 due to their incomplete absorption by the preceding *D. discoideum* lysosomal enzyme-Sepharose 4B column.

the D. discoideum lysosomal enzyme-Sepharose 4B column, only MPR-215 (and fragments thereof) was detectable (not shown). MPR-46 was detectable only in the eluent from the phosphomannan-Sepharose 4B column (fig.2). Substitution of the binding and washing buffers with either 10 mM MnCl₂/1 mM EDTA or 1 mM EDTA yielded similar amounts of MPR-46 polypeptides. The monomeric forms of MPR-46 were accompanied by a small fraction of dimeric receptor forms, which was resistant against boiling in the presence of SDS and dithiothreitol. Dimeric forms were noted earlier in receptor preparations from bovine [2] and human [6] liver. In contrast to liver, several

distinct forms of monomeric and dimeric forms of MPR-46 were discernible in brain. The molecular basis for this heterogeneity is presently under investigation.

4. DISCUSSION

Previous investigations had established an absolute requirement for divalent cations for high-affinity binding of MPR-46 [2,3,11,12]. Here, such a dependence was not detectable. The specificity of binding in the absence of divalent cations was sufficient to allow purification of the receptor from crude tissue extracts by affinity chromatography. Moreover, the yield in the absence or presence of divalent cations was comparable.

Cation dependence was established for MPR-46 from bovine liver [2]. It is possible that species variations account for the differences in cation requirement. However, the cation requirement may also depend on the type of affinity matrix. Cation dependence was observed for affinity matrices in which the phosphomannan was coupled directly to Sepharose 4B [2], while cation independence is observed with affinity matrices in which the phosphomannan is coupled via a six-carbon-long spacer [6]. Our initial attempts to prepare affinity matrices for MPR-46 by coupling phosphomannan directly to Sepharose 4B, yielded gels with unsatisfactory binding capacities (Stein, M. unpublished). It is therefore conceivable that high concentrations of divalent cations improve the interaction of MPR-46 with ligands if the accessibility of the latter is unfavorable.

The present observation of cation-independent binding of ligands to MPR-46 has precendents. Membranes of Morris hepatoma cells, which express only MPR-46, retain 60% or more of their mannose 6-phosphate-binding sites in the presence of 10 mM EGTA [4]. Distler and Jourdian [13,14] purified a cation-independent MPR from bovine testes of apparent molecular mass 42 kDa. At low

 β -galactosidase concentrations binding of β -galactosidase with the receptor was improved by high concentrations (20 mM) of MnCl₂.

The present results and earlier observations indicate the need for caution in attempts to discriminate between MPR-46 and MPR-215 solely on the basis of cation dependence. Furthermore, it appears more appropriate to designate the smaller of the two receptors according to molecular mass (MPR-46) than according to its cation requirement (MPR^{CD}).

Acknowledgements: This work was supported by the Deutsche Forschungsgemeinschaft (SFB 236) and the Fonds der Chemischen Industrie.

REFERENCES

- Sahagian, G.G., Distler, J. and Jourdian, G.W. (1981) Proc. Natl. Acad. Sci. USA 78, 4289-4293.
- [2] Hoflack, B. and Kornfeld, S. (1985) J. Biol. Chem. 260, 12008-12014
- [3] Duncan, J.R. and Kornfeld, S. (1988) J. Cell Biol. 106, 617-628.
- [4] Stein, M., Zijderhand-Bleekemolen, Geuze, H., Hasilik, A. and Von Figura, K. (1987) EMBO J. 6, 2677-2681.
- [5] Braulke, T., Gartung, C., Hasilik, A. and Von Figura, K. (1987) J. Cell Biol. 104, 1735-1742.
- [6] Stein, M., Meyer, H.E., Hasilik, A. and Von Figura, K. (1987) Biol. Chem. Hoppe Seyler 368, 927-936.
- [7] Parker, K.C. and Strominger, J.C. (1983) Biochemistry 22, 1145-1153.
- [8] Von Figura, K., Gieselmann, V. and Hasilik, A. (1984) EMBO J. 3, 1281-1286.
- [9] Laemmli, U.K. (1969) Nature 227, 680-685.
- [10] Zühlsdorf, M., Imort, M., Hasilik, A. and Von Figura, K. (1983) Biochem. J. 213, 733-740.
- [11] Hoflack, B. and Kornfeld, S. (1985) Proc. Natl. Acad. Sci. USA 82, 4428-4432.
- [12] Hoflack, B., Fumjimoto, K. and Kornfeld, S. (1987) J. Biol. Chem. 262, 123-129.
- [13] Distler, J. and Jourdian, G.W. (1986) Fed. Proc. 45, 1900.
- [14] Distler, J. and Jourdian, G.W. (1987) Methods Enzymol. 138, 504-509.
- [15] Morgan, D.O., Edman, J.C., Standring, D.N., Fried, V.A., Smith, M.C., Roth, R.A. and Rutter, W.J. (1987) Nature 329, 301-307.